Si-Qi Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Si-Qi Qiu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Zhiyong Wu
Shantou Clinical Medical College of Jinan University (Shantou Central Hospital), Jinan University
4 shared publicationsHai-Lu Chen
Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China
3 shared publicationsJiahui Wang
Shantou Clinical Medical College of Jinan University (Shantou Central Hospital), Jinan University
3 shared publicationsJiatian Song
Cancer Hospital of Shantou University Medical College
3 shared publicationsJunwei Li
Shantou Clinical Medical College of Jinan University (Shantou Central Hospital), Jinan University
3 shared publicationsMenglong Zhao
Shantou Clinical Medical College of Jinan University (Shantou Central Hospital), Jinan University
3 shared publications
Latest Publications
- 19 September 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (38) , 52142-52153
Exploring Aza-BODIPY Derivatives as Sonosensitizers for Deep-Tissue Sonotheranostics in Breast Cancer
Sonodynamic therapy (SDT) is an emerging noninvasive treatment for tumors with the advantage of deep tissue penetration. However, it is still challenging to develop effective organic sonosensitizers with good stability for imaging and SDT. In this work, in order to reveal the structure–activity relationship of sonosensitizers, we designed and synthesized a series of aza-BODIPY derivatives (AB1–AB5) with different substituents (methoxy, octyloxy, anthracene, and iodine atom) to systematically evaluate the influence of electron-donating effect and heavy atom effect on the sonodynamic efficacy. Among them, the iodine-substituted aza-BODIPY (AB5) demonstrated superior sonodynamic performance and exhibited enhanced reactive oxygen species (ROS) generation. Subsequently, we encapsulated AB5 with the hydrophilic polymer DSPE-mPEG2000 to create nanoparticles referred to as iodinated aza-BODIPY nanoparticles (IABNPs). In vitro cellular assays and in vivo animal experiments showed that IABNPs had excellent stability, biocompatibility, and pronounced sonodynamic effect, which resulted in significant inhibition of tumor growth. Moreover, the fluorescent emission characteristics of AB5 enabled fluorescence-guided imaging and real-time monitoring during tumor treatment. This study systematically explored the influence of substituents on the sonodynamic effect of aza-BODIPY, providing important theoretical foundations and perspectives for future research in related fields.
- 19 September 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (38) , 52142-52153
Exploring Aza-BODIPY Derivatives as Sonosensitizers for Deep-Tissue Sonotheranostics in Breast Cancer
Sonodynamic therapy (SDT) is an emerging noninvasive treatment for tumors with the advantage of deep tissue penetration. However, it is still challenging to develop effective organic sonosensitizers with good stability for imaging and SDT. In this work, in order to reveal the structure–activity relationship of sonosensitizers, we designed and synthesized a series of aza-BODIPY derivatives (AB1–AB5) with different substituents (methoxy, octyloxy, anthracene, and iodine atom) to systematically evaluate the influence of electron-donating effect and heavy atom effect on the sonodynamic efficacy. Among them, the iodine-substituted aza-BODIPY (AB5) demonstrated superior sonodynamic performance and exhibited enhanced reactive oxygen species (ROS) generation. Subsequently, we encapsulated AB5 with the hydrophilic polymer DSPE-mPEG2000 to create nanoparticles referred to as iodinated aza-BODIPY nanoparticles (IABNPs). In vitro cellular assays and in vivo animal experiments showed that IABNPs had excellent stability, biocompatibility, and pronounced sonodynamic effect, which resulted in significant inhibition of tumor growth. Moreover, the fluorescent emission characteristics of AB5 enabled fluorescence-guided imaging and real-time monitoring during tumor treatment. This study systematically explored the influence of substituents on the sonodynamic effect of aza-BODIPY, providing important theoretical foundations and perspectives for future research in related fields.
- Open Access
- 10 March 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (8) , 1706-1717
A pH/ATP Dual-Sensitive Nanoprobe-Based Bioluminescence Imaging for Intraoperative Human Multicancer Detection
Current intraoperative cancer diagnosis predominantly relies on frozen section histopathology, which is time-consuming and prone to sampling bias. Development of techniques for intraoperative cancer diagnosis is urgently needed. Notably, malignant tumors manifest distinctive microenvironmental signatures characterized by acidic pH gradients and elevated ATP concentrations, which are important biomarkers for tumor identification. Based on these signatures, a pH/ATP dual-sensitive bioluminescent nanoprobe, d-luciferase-liposome-PEOz (DLPNPs), was engineered using thin-film hydration. The nanoprobe displayed a spherical morphology (∼140 nm in diameter), low pH-dependent activation (pH <6.5), and good biocompatibility in vitro. Ex vivo bioluminescence imaging of freshly resected specimens from five murine tumor models (breast, liver, colon, lung, and tongue) and five human cancer types (breast, colorectal, endometrial, lung, and gastric) demonstrated significantly elevated tumor signals compared to normal tissues. The median tumor-to-background ratios (TBRs) were 21.49 (IQR, 8.86–105.7) in mice and 47.89 (IQR, 5.27–238.9) in humans. The nanoprobe achieved 100% sensitivity and 100% specificity in cancer diagnosis, with an area under the curve (AUC) of 1.00 across all cancer types evaluated in both mouse and human tissues. Microscopic analysis further confirmed precise colocalization between bioluminescent signals and malignant regions. Notably, the entire workflow, from nanoprobe application to image acquisition, requires less than 10 min. These findings indicate that DLPNPs enable rapid and accurate intraoperative tumor diagnosis by leveraging tumor microenvironmental signatures. The multicancer applicability, high TBR, and streamlined workflow indicate that DLPNPs are worthy of further evaluation for clinical translation in future studies with larger sample sizes and more diverse cancer cohorts.
- 10 March 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (8) , 1706-1717
Open AccessA pH/ATP Dual-Sensitive Nanoprobe-Based Bioluminescence Imaging for Intraoperative Human Multicancer Detection
Current intraoperative cancer diagnosis predominantly relies on frozen section histopathology, which is time-consuming and prone to sampling bias. Development of techniques for intraoperative cancer diagnosis is urgently needed. Notably, malignant tumors manifest distinctive microenvironmental signatures characterized by acidic pH gradients and elevated ATP concentrations, which are important biomarkers for tumor identification. Based on these signatures, a pH/ATP dual-sensitive bioluminescent nanoprobe, d-luciferase-liposome-PEOz (DLPNPs), was engineered using thin-film hydration. The nanoprobe displayed a spherical morphology (∼140 nm in diameter), low pH-dependent activation (pH <6.5), and good biocompatibility in vitro. Ex vivo bioluminescence imaging of freshly resected specimens from five murine tumor models (breast, liver, colon, lung, and tongue) and five human cancer types (breast, colorectal, endometrial, lung, and gastric) demonstrated significantly elevated tumor signals compared to normal tissues. The median tumor-to-background ratios (TBRs) were 21.49 (IQR, 8.86–105.7) in mice and 47.89 (IQR, 5.27–238.9) in humans. The nanoprobe achieved 100% sensitivity and 100% specificity in cancer diagnosis, with an area under the curve (AUC) of 1.00 across all cancer types evaluated in both mouse and human tissues. Microscopic analysis further confirmed precise colocalization between bioluminescent signals and malignant regions. Notably, the entire workflow, from nanoprobe application to image acquisition, requires less than 10 min. These findings indicate that DLPNPs enable rapid and accurate intraoperative tumor diagnosis by leveraging tumor microenvironmental signatures. The multicancer applicability, high TBR, and streamlined workflow indicate that DLPNPs are worthy of further evaluation for clinical translation in future studies with larger sample sizes and more diverse cancer cohorts.
- Open Access
- 4 November 2025
- Published by Elsevier in Materials & Design
- Vol. 260
NIR Image-Guided Multimodal Nanotherapy Synergizing Photothermal, NO Gas, and Ferroptosis Enhances Immunogenic Cell Death in Triple-Negative Breast Cancer
- 4 November 2025
- Published by Elsevier in Materials & Design
- Vol. 260
Open AccessNIR Image-Guided Multimodal Nanotherapy Synergizing Photothermal, NO Gas, and Ferroptosis Enhances Immunogenic Cell Death in Triple-Negative Breast Cancer
- 20 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 116056
Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study
- 20 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 116056
Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study
- 21 January 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (6) , 2171-2186
GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer
Purpose Precise tumor excision is important but challenging in breast-conserving surgery (BCS). Tumor-specific fluorescence imaging may be used for intraoperative tumor detection and, therefore, to guide precise tumor excision. The aims of this study are to develop a glucose transporter 1 (GLUT1)-targeted near-infrared fluorescence tracer and evaluate its accuracy for breast cancer detection using fresh surgical breast specimens. Methods Bioinformatic analysis was performed to compare GLUT1 expression between breast cancer and normal breast tissues. A GLUT1-targeted fluorescence imaging tracer WZB117-CY7.5 was developed. In combination with fluorescence imaging (FMI), its binding specificity to GLUT1 was examined in in vitro breast cancer cell experiments, in vivo 4T1 breast tumor-bearing mouse models, and 60 freshly resected human breast tumor tissues. The diagnostic accuracy of WZB117-CY7.5, was evaluated in fresh specimens derived from 60 patients diagnosed with breast cancer. Results GLUT1 expression is higher in breast cancer tissues compared with normal tissues. WZB117-CY7.5 specifically bound to breast cancer cells in in vitro cell experiments and accumulated in tumor areas in a 4T1 tumor-bearing mice after intravenous injection by FMI. Moreover, WZB117-CY7.5 specifically bound to freshly resected human breast cancer and demonstrated excellent diagnostic performance in discriminating breast cancer, irrespective of cancer subtype, from normal breast tissue on fresh surgically resected breast tissues. Conclusions WZB117-CY7.5 showed high accuracy in intraoperative breast cancer detection, irrespective of the cancer subtype. This highlights its potential for clinical applications as a generic tracer for fluorescence image-guided surgery (FIGS) in BCS and fluorescence image-guided pathology for tissue sampling.
- 21 January 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (6) , 2171-2186
GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer
Purpose Precise tumor excision is important but challenging in breast-conserving surgery (BCS). Tumor-specific fluorescence imaging may be used for intraoperative tumor detection and, therefore, to guide precise tumor excision. The aims of this study are to develop a glucose transporter 1 (GLUT1)-targeted near-infrared fluorescence tracer and evaluate its accuracy for breast cancer detection using fresh surgical breast specimens. Methods Bioinformatic analysis was performed to compare GLUT1 expression between breast cancer and normal breast tissues. A GLUT1-targeted fluorescence imaging tracer WZB117-CY7.5 was developed. In combination with fluorescence imaging (FMI), its binding specificity to GLUT1 was examined in in vitro breast cancer cell experiments, in vivo 4T1 breast tumor-bearing mouse models, and 60 freshly resected human breast tumor tissues. The diagnostic accuracy of WZB117-CY7.5, was evaluated in fresh specimens derived from 60 patients diagnosed with breast cancer. Results GLUT1 expression is higher in breast cancer tissues compared with normal tissues. WZB117-CY7.5 specifically bound to breast cancer cells in in vitro cell experiments and accumulated in tumor areas in a 4T1 tumor-bearing mice after intravenous injection by FMI. Moreover, WZB117-CY7.5 specifically bound to freshly resected human breast cancer and demonstrated excellent diagnostic performance in discriminating breast cancer, irrespective of cancer subtype, from normal breast tissue on fresh surgically resected breast tissues. Conclusions WZB117-CY7.5 showed high accuracy in intraoperative breast cancer detection, irrespective of the cancer subtype. This highlights its potential for clinical applications as a generic tracer for fluorescence image-guided surgery (FIGS) in BCS and fluorescence image-guided pathology for tissue sampling.
- 20 January 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 210 (3) , 709-718
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study
Purpose Precise tumor excision is important in breast-conserving surgery (BCS). This study explores the safety and accuracy of fluorescence image-guided BCS (FIGS) using a lidocaine mucilage-ICG compound (L-ICG). Methods 54 patients who underwent BCS from August 2020 to September 2023 were enrolled. L-ICG was locally injected 0.5 cm from the tumor border. FIGS was performed to guide the tumor excision. Frozen sectioning of surgical field biopsies was used to assess the intraoperative margin status. The primary outcome measures were margin width and positive margin rates. Cosmetic outcome was evaluated by the modified version of Breast-QTM Breast-Conserving Therapy Module (Postoperative) and breast cosmetic outcome assessment criteria. Results The median cranial, caudal, medial, and lateral margin widths were 8 mm (interquartile range [IQR], 3–14), 5.5 mm (IQR, 2–15), 6 mm (IQR, 3–15), and 8 mm (IQR, 3–15), respectively. Five out of 54 (9.3%) patients had an intraoperative positive margin. Intraoperatively extended resection was performed for four patients and mastectomy for the remaining one. This further reduced the positive margin rate to 1.9% at final histopathology. 50 patients received cosmetic outcome evaluation, 100% of them were “somewhat satisfied” or “very satisfied” with the appearance of the operated breast when clothed and 98% of them were scaled as “Good” or "Excellent" in their appearance of the operated breast. No serious adverse events were observed. With a median follow-up of 12.8 months, no events for tumor relapse were observed. Conclusion L-ICG-based FIGS is a promising technique to guide precise tumor excision in BCS.
- 20 January 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 210 (3) , 709-718
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study
Purpose Precise tumor excision is important in breast-conserving surgery (BCS). This study explores the safety and accuracy of fluorescence image-guided BCS (FIGS) using a lidocaine mucilage-ICG compound (L-ICG). Methods 54 patients who underwent BCS from August 2020 to September 2023 were enrolled. L-ICG was locally injected 0.5 cm from the tumor border. FIGS was performed to guide the tumor excision. Frozen sectioning of surgical field biopsies was used to assess the intraoperative margin status. The primary outcome measures were margin width and positive margin rates. Cosmetic outcome was evaluated by the modified version of Breast-QTM Breast-Conserving Therapy Module (Postoperative) and breast cosmetic outcome assessment criteria. Results The median cranial, caudal, medial, and lateral margin widths were 8 mm (interquartile range [IQR], 3–14), 5.5 mm (IQR, 2–15), 6 mm (IQR, 3–15), and 8 mm (IQR, 3–15), respectively. Five out of 54 (9.3%) patients had an intraoperative positive margin. Intraoperatively extended resection was performed for four patients and mastectomy for the remaining one. This further reduced the positive margin rate to 1.9% at final histopathology. 50 patients received cosmetic outcome evaluation, 100% of them were “somewhat satisfied” or “very satisfied” with the appearance of the operated breast when clothed and 98% of them were scaled as “Good” or "Excellent" in their appearance of the operated breast. No serious adverse events were observed. With a median follow-up of 12.8 months, no events for tumor relapse were observed. Conclusion L-ICG-based FIGS is a promising technique to guide precise tumor excision in BCS.
- Open Access
- 19 December 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells
CD8+ T cell spatial distribution in the context of tumor microenvironment (TME) dictates the immunophenotypes of tumors, comprised of immune-infiltrated, immune-excluded and immune-desert, discriminating “hot” from “cold” tumors. The infiltration of cytotoxic CD8+ T cells is associated with favorable therapeutic response. Hitherto, the immunophenotypes of esophageal squamous cell carcinoma (ESCC) have not yet been comprehensively delineated. Herein, we comprehensively characterized the immunophenotypes of ESCC and identified a subset of ESCC, which was defined as cold tumor and characterized with CD8+ T cell-desert TME. However, the mechanism underlying the defect of CD8+ T cells in TME is still pending. Herein, we uncovered that tumor cell-intrinsic EZH2 with high expression was associated with the immunophenotype of immune-desert tumors. Targeted tumor cell-intrinsic EZH2 rewired the transcriptional activation of CXCL9 mediated by NF-κB and concomitantly reinvigorated DC maturation differentiation via inducing the reduction of VEGFC secretion, thereby enhancing the infiltration of cytotoxic CD8+ T cells into TME and inhibiting tumor immune evasion. Our findings identify EZH2 as a potential therapeutic target and point to avenues for targeted therapy applied to patients with ESCC characterized by CD8+ T cell-desert tumors.
- 19 December 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Open AccessEZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells
CD8+ T cell spatial distribution in the context of tumor microenvironment (TME) dictates the immunophenotypes of tumors, comprised of immune-infiltrated, immune-excluded and immune-desert, discriminating “hot” from “cold” tumors. The infiltration of cytotoxic CD8+ T cells is associated with favorable therapeutic response. Hitherto, the immunophenotypes of esophageal squamous cell carcinoma (ESCC) have not yet been comprehensively delineated. Herein, we comprehensively characterized the immunophenotypes of ESCC and identified a subset of ESCC, which was defined as cold tumor and characterized with CD8+ T cell-desert TME. However, the mechanism underlying the defect of CD8+ T cells in TME is still pending. Herein, we uncovered that tumor cell-intrinsic EZH2 with high expression was associated with the immunophenotype of immune-desert tumors. Targeted tumor cell-intrinsic EZH2 rewired the transcriptional activation of CXCL9 mediated by NF-κB and concomitantly reinvigorated DC maturation differentiation via inducing the reduction of VEGFC secretion, thereby enhancing the infiltration of cytotoxic CD8+ T cells into TME and inhibiting tumor immune evasion. Our findings identify EZH2 as a potential therapeutic target and point to avenues for targeted therapy applied to patients with ESCC characterized by CD8+ T cell-desert tumors.
- Open Access
- 14 October 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
CD74 is a potential biomarker predicting the response to immune checkpoint blockade
Immune checkpoint blockade (ICB) has been improving the patient outcome in multiple cancer types. However, not all patients respond to ICB. Biomarkers are needed for selecting appropriate patients to receive ICB. CD74 is an important chaperone that regulates antigen presentation for immune response. However, the relationship between CD74 expression and ICB response remains elusive. The unified normalized pan-cancer dataset was downloaded from the UCSC database. Wilcoxon Rank Sum Rank Tests were used to analyze the expression differences between normal and tumor samples in each tumor type. Then, the prognostic value of CD74 was determined using univariable Cox proportional hazards regression analysis. The STRING database was utilized to construct the protein-protein interaction (PPI) network of CD74 and the signal pathways were analyzed as well. The correlation of CD74 expression with immune cells and immune regulating genes was investigated in the TIMER database. The TIDE framework was utilized to evaluate the relationship between CD74 expression and the response to immunotherapy. Moreover, the localization of CD74 in the tumor immune microenvironment was verified using multiplex immunohistochemistry. Clinically annotated samples from 38 patients with esophageal cancer treated with neoadjuvant chemotherapy combined with ICB were analyzed for CD74 expression using immunohistochemistry. In this study, we investigated the prognostic and predictive value of CD74 in different types of cancer. Compared with normal tissue, the expression of CD74 was higher in tumor tissue in various cancers. High expression of CD74 was associated with improved patient prognosis in the majority of cancers. CD74 and its interacting proteins were mainly enriched in the immune-related pathways. The expression of CD74 was significantly positively correlated with B cells, CD4 T-cells, CD8 T-cells, neutrophils, macrophages and dendritic cells. TIDE analysis showed that tumors with high CD74 expression may have better responses to immunotherapy and improved patient survival. In patients with esophageal cancer who had received ICB, higher intratumoral CD74 expression was associated with improved response to ICB. The findings of this study suggest that the high expression of CD74 may be a potential predictive biomarker of response to ICB.
- 14 October 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Open AccessCD74 is a potential biomarker predicting the response to immune checkpoint blockade
Immune checkpoint blockade (ICB) has been improving the patient outcome in multiple cancer types. However, not all patients respond to ICB. Biomarkers are needed for selecting appropriate patients to receive ICB. CD74 is an important chaperone that regulates antigen presentation for immune response. However, the relationship between CD74 expression and ICB response remains elusive. The unified normalized pan-cancer dataset was downloaded from the UCSC database. Wilcoxon Rank Sum Rank Tests were used to analyze the expression differences between normal and tumor samples in each tumor type. Then, the prognostic value of CD74 was determined using univariable Cox proportional hazards regression analysis. The STRING database was utilized to construct the protein-protein interaction (PPI) network of CD74 and the signal pathways were analyzed as well. The correlation of CD74 expression with immune cells and immune regulating genes was investigated in the TIMER database. The TIDE framework was utilized to evaluate the relationship between CD74 expression and the response to immunotherapy. Moreover, the localization of CD74 in the tumor immune microenvironment was verified using multiplex immunohistochemistry. Clinically annotated samples from 38 patients with esophageal cancer treated with neoadjuvant chemotherapy combined with ICB were analyzed for CD74 expression using immunohistochemistry. In this study, we investigated the prognostic and predictive value of CD74 in different types of cancer. Compared with normal tissue, the expression of CD74 was higher in tumor tissue in various cancers. High expression of CD74 was associated with improved patient prognosis in the majority of cancers. CD74 and its interacting proteins were mainly enriched in the immune-related pathways. The expression of CD74 was significantly positively correlated with B cells, CD4 T-cells, CD8 T-cells, neutrophils, macrophages and dendritic cells. TIDE analysis showed that tumors with high CD74 expression may have better responses to immunotherapy and improved patient survival. In patients with esophageal cancer who had received ICB, higher intratumoral CD74 expression was associated with improved response to ICB. The findings of this study suggest that the high expression of CD74 may be a potential predictive biomarker of response to ICB.
- Open Access
- 10 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy. We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs. Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs. We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.
- 10 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Open AccessPan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy. We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs. Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs. We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.
- 27 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 28 (8) , 4688-4700
Self-Supervised Image Denoising of Third Harmonic Generation Microscopic Images of Human Glioma Tissue by Transformer-Based Blind Spot (TBS) Network
Third harmonic generation (THG) microscopy shows great potential for instant pathology of brain tumor tissue during surgery. However, due to the maximal permitted exposure of laser intensity and inherent noise of the imaging system, the noise level of THG images is relatively high, which affects subsequent feature extraction analysis. Denoising THG images is challenging for modern deep-learning based methods because of the rich morphologies contained and the difficulty in obtaining the noise-free counterparts. To address this, in this work, we propose an unsupervised deep-learning network for denoising of THG images which combines a self-supervised blind spot method and a U-shape Transformer using a dynamic sparse attention mechanism. The experimental results on THG images of human glioma tissue show that our approach exhibits superior denoising performance qualitatively and quantitatively compared with previous methods. Our model achieves an improvement of 2.47-9.50 dB in SNR and 0.37-7.40 dB in CNR, compared to six recent state-of-the-art unsupervised learning models including Neighbor2Neighbor, Blind2Unblind, Self2Self+, ZS-N2N, Noise2Info and SDAP. To achieve an objective evaluation of our model, we also validate our model on public datasets including natural and microscopic images, and our model shows a better denoising performance than several recent unsupervised models such as Neighbor2Neighbor, Blind2Unblind and ZS-N2N. In addition, our model is nearly instant in denoising a THG image, which has the potential for real-time applications of THG microscopy.
- 27 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 28 (8) , 4688-4700
Self-Supervised Image Denoising of Third Harmonic Generation Microscopic Images of Human Glioma Tissue by Transformer-Based Blind Spot (TBS) Network
Third harmonic generation (THG) microscopy shows great potential for instant pathology of brain tumor tissue during surgery. However, due to the maximal permitted exposure of laser intensity and inherent noise of the imaging system, the noise level of THG images is relatively high, which affects subsequent feature extraction analysis. Denoising THG images is challenging for modern deep-learning based methods because of the rich morphologies contained and the difficulty in obtaining the noise-free counterparts. To address this, in this work, we propose an unsupervised deep-learning network for denoising of THG images which combines a self-supervised blind spot method and a U-shape Transformer using a dynamic sparse attention mechanism. The experimental results on THG images of human glioma tissue show that our approach exhibits superior denoising performance qualitatively and quantitatively compared with previous methods. Our model achieves an improvement of 2.47-9.50 dB in SNR and 0.37-7.40 dB in CNR, compared to six recent state-of-the-art unsupervised learning models including Neighbor2Neighbor, Blind2Unblind, Self2Self+, ZS-N2N, Noise2Info and SDAP. To achieve an objective evaluation of our model, we also validate our model on public datasets including natural and microscopic images, and our model shows a better denoising performance than several recent unsupervised models such as Neighbor2Neighbor, Blind2Unblind and ZS-N2N. In addition, our model is nearly instant in denoising a THG image, which has the potential for real-time applications of THG microscopy.